Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.53 |
| ▸ | GSK3B | P49841 | 10/20 | 0.53 |
| ▸ | GSK3A | P49840 | 8/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589735 | 0.85 | GSK3B (0.53) | AURKAGSK3BGSK3AJAK2AURKB | |
| SCHEMBL1353795 | 0.83 | DCLK1 (0.52) | AURKA | |
| SCHEMBL3579319 | 0.82 | GSK3B (0.50) | AURKAGSK3BGSK3AJAK2AURKB | |
| SCHEMBL1355558 | 0.81 | CDK1 (0.48) | AURKA | |
| SCHEMBL1355881 | 0.80 | STAT6 (0.57) | AURKAJAK2AURKB | |
| SCHEMBL1353817 | 0.79 | CDK4 (0.36) | AURKAGSK3BGSK3AAURKB | |
| SCHEMBL1355286 | 0.79 | CDK4 (0.59) | AURKAJAK2 | |
| SCHEMBL1353840 | 0.79 | CDK4 (0.54) | JAK2 | |
| SCHEMBL1355866 | 0.78 | CDK4 (0.47) | AURKAAURKB | |
| SCHEMBL1353786 | 0.74 | EIF2AK4 (0.62) | AURKAGSK3BGSK3AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | AURKA 9/4885GSK3B 261/4885GSK3A 277/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | AURKA 9/4885GSK3B 261/4885GSK3A 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.